絞り込み

16399

広告

「"Lacouture ME"[Author]」の検索結果

179件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Granuloma annulare associated with immune checkpoint inhibitors.

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: A review of controlled clinical trials.

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Olmutinib-induced palmoplantar keratoderma.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Post-reconstruction dermatitis of the breast.

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Oral Lichenoid Reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Treatment (Tx) guidelines for skin and mucosal events in patients with solid tumors (pts) receiving TH-302, a tumor selective, hypoxia-activated prodrug.

Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib.

Management of dermatologic toxicities associated with epidermal growth factor inhibitors (EGFRIs) and multikinase inhibitors (MKIs).

Quality of life in patients with dermatologic toxicities: Experience from the SERIES clinic.

Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

Risk of rash and stomatitis with everolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a setting of chemotherapy treatment: An assessment of FDA MedWatch database.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります